Status:
COMPLETED
A Study of Brain Receptor Occupancy in Healthy Subjects
Lead Sponsor:
Eli Lilly and Company
Conditions:
Alcohol Dependence
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.
Eligibility Criteria
Inclusion
- Healthy male or female
- Have clinical laboratory tests within normal reference ranges
- Have arterial and venous access sufficient to allow blood sampling
Exclusion
- Currently enrolled in, or discontinued within the last 30 days from a clinical trial
- History of severe allergies or multiple adverse drug reactions
- Have an abnormal ECG at screening visit
- Have abnormal sitting blood pressure
- Have an increased risk of seizures
- Current suicidal ideation
- Positive test for HIV, hepatitis C, or hepatitis B
- Women who are breast feeding
- Smoke more than 10 cigarettes per day, or equivalent
- Drink more than 5 cups of coffee per day, or equivalent
- Have a history of head injury
- Unable to undergo a MRI
- Suffer from claustrophobia
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01232439
Start Date
December 1 2010
End Date
April 1 2011
Last Update
May 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
New Haven, Connecticut, United States, 06519